Obesity Surgery

, Volume 28, Issue 8, pp 2429–2438 | Cite as

The Effects of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Japanese Patients with BMI < 35 kg/m2 on Type 2 Diabetes Mellitus and the Prediction of Successful Glycemic Control

  • Yosuke Seki
  • Kazunori Kasama
  • Kazuki Yasuda
  • Renzo Yokoyama
  • Jose Paolo Porciuncula
  • Yoshimochi Kurokawa
Original Contributions



Laparoscopic sleeve gastrectomy with duodenojejunal bypass (LSG-DJB) is a combination of sleeve gastrectomy and proximal intestinal bypass through duodenal exclusion. This technique has shown excellent weight loss and anti-diabetic effects in severely obese patients. In this retrospective study, we examined the clinical effects of LSG-DJB on mildly obese patients (body mass index (BMI) < 35 kg/m2) with type 2 diabetes mellitus (T2DM) and analyzed factors contributing to the successful postoperative glycemic control.


Seventy-two consecutive Japanese patients with T2DM with a BMI of < 35 kg/m2 who underwent LSG-DJB in a single institution from September 2007 to March 2015 were included for the study. Weight loss, safety, and the impact on T2DM and metabolic syndrome were examined at 1 year after surgery when weight loss reaches an expected plateau. In addition, pre- and postoperative factors between those who achieved diabetes remission (remitters) and non-remitters were compared.


The follow-up rate at 1 year after surgery was 93%. The mean percent total weight loss (%TWL) was 31.6 ± 8.8%, and the mean glycosylated hemoglobin (HbA1c) dropped from 8.9 ± 1.5 to 6.4 ± 1.0%. There were four early- and seven late-severe complications (grade III-A or more based on the Clavien-Dindo classification), which account for the 1-year morbidity rate of 15%. There was no mortality. The complete (HbA1c of < 6% without diabetes medication) and partial (HbA1c of < 6.5% without diabetes medication) remission of T2DM was achieved in 31 and 49% of the patients, respectively. Positive impacts were also observed on hypertension and dyslipidemia. Consequently, the ratio of those who achieved the composite endpoint (HbA1c of < 7%, low-density lipoprotein cholesterol < 100 mg/dL, systolic blood pressure < 130 mmHg) significantly increased from 4.2 to 22% (p = 0.003). Duration of T2DM and preoperative use of anti-hypertensive drugs were independent predictors of diabetes remission. Patients with a higher ABCD score were also at a higher rate of success in T2DM remission.


LSG-DJB for T2DM patients with a BMI of < 35 kg/m2 is a feasible and effective surgical method in achieving moderate weight loss and excellent improvement of glycemic control, metabolic syndrome, and cardiovascular risk although the T2DM remission rate was lower compared with severely obese individuals. Proper patient selection for candidates of the procedure is imperative to effectively predict poor responders.


LSG-DJB Japanese Diabetes Class I obesity Metabolic surgery 



The authors wish to thank Dr. Jose Paolo Porciuncula, who assisted in the proofreading of this manuscript. We also thank Drs. Mitsuhiko Noda, Ritsuko Yamamoto-Honda, and Maki Goto for helpful discussion on the study design.

Funding Information

This study was partially supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NiBio).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Ethical Approval

All procedures performed in our study involving human participants were in accordance with the ethical standards of the institutional and/or Japanese national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in our study.


  1. 1.
    Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.CrossRefPubMedGoogle Scholar
  2. 2.
    Rao WS, Shan CX, Zhang W, et al. A meta-analysis of short-term outcomes of patients with type 2 diabetes mellitus and BMI ≤ 35 kg/m2 undergoing Roux-en-Y gastric bypass. World J Surg. 2015;39:223–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Cummings DE, Cohen RV. Bariatric/metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care. 2016;39:924–33.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Malapan K, Goel R, Tai CM, et al. Laparoscopic Roux-en-Y gastric bypass for nonobese type II diabetes mellitus in Asian patients. Surg Obes Relat Dis. 2014;10:834–40.CrossRefPubMedGoogle Scholar
  5. 5.
    Huang CK, Shabbir A, Lo CH, et al. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25-35. Obes Surg. 2011;21:1344–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rubino F, Shukla A, Pomp A, et al. Bariatric, metabolic, and diabetes surgery: what's in a name? Ann Surg. 2014;259:117–22.CrossRefPubMedGoogle Scholar
  7. 7.
    Kasama K, Tagaya N, Seki Y, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass: technique and preliminary results. Obes Surg. 2009;19:1341–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Tagaya N, Kasama K, Inamine S, et al. Evaluation of the excluded stomach by double-balloon endoscopy after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2007;17:1165–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Seki Y, Kasama K, Umezawa A, et al. Laparoscopic sleeve gastrectomy with duodenojejunal bypass for type 2 diabetes mellitus. Obes Surg. 2016;26:2035–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Seki Y, Kasama K, Haruta H, et al. Five-year-results of laparoscopic sleeve gastrectomy with duodenojejunal bypass for weight loss and type 2 diabetes mellitus. Obes Surg. 2017;27:795–801.CrossRefPubMedGoogle Scholar
  11. 11.
    Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    American Diabetes Association. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(Suppl 1):S13–61.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Lee WJ, Hur KY, Lakadawala M, et al. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis. 2013;9:379–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    International Diabetes Federation. Diabetes Atlas. 7th ed. Brussels, Belgium: International Diabetes Federation; 2015.Google Scholar
  16. 16.
    Moller JB, Pedersen M, Tanaka H, et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 2014;37:796–804.Google Scholar
  17. 17.
    Sone H, Yamada N, Akanuma Y, et al. Japan diabetes complication study. J Clin and Exp Med. 2007;220:1275–81.Google Scholar
  18. 18.
    Boffetta P, McLerran D, Chen Y, et al. Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One. 2011;6:e19930.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol. 2014;2:38–45.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36:20–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Panunzi S, Carlsson L, De Gaetano A, et al. Determinants of diabetes remission and glycemic control after bariatric surgery. Diabetes Care. 2016;39:166–74.CrossRefPubMedGoogle Scholar
  22. 22.
    Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420–8.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.CrossRefPubMedGoogle Scholar
  24. 24.
    Dixon JB, Hur KY, Lee WJ, et al. Gastric bypass in type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet Med. 2013;30:e127–34.CrossRefPubMedGoogle Scholar
  25. 25.
    Bose M, Teixeira J, Scherer PE, et al. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes. 2010;2:47–55.CrossRefPubMedGoogle Scholar
  26. 26.
    Laferrère B, Heshka S, Wang K, et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Lee WJ, Almulaifi A, Tsou JJ, et al. Laparoscopic sleeve gastrectomy for type 2 diabetes mellitus: predicting the success by ABCD score. Surg Obes Relat Dis. 2015;11:991–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Lee WJ, Almulaifi A, Chong K, et al. The effect and predictive score of gastric bypass and sleeve gastrectomy on type 2 diabetes mellitus patients with BMI < 30 kg/m2. Obes Surg. 2015;25:1772–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Lee WJ, Chong K, Chen SC, et al. Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg. 2016;26:2418–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Haruta H, Kasama K, Seki Y, et al. Long-term outcomes of bariatric and metabolic surgery in Japan: results of a multi-institutional survey. Obes Surg. 2017;27:754–62.CrossRefPubMedGoogle Scholar
  31. 31.
    Scopinaro N, Adami GF, Papadia FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253:699–703.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Weight Loss and Metabolic Surgery CenterYotsuya Medical CubeTokyoJapan
  2. 2.Department of Metabolic Disorder, Diabetes Research Center, Research InstituteNational Center for Global Health and MedicineTokyoJapan
  3. 3.Center for Clinical ResearchOkinawa Prefectural Chubu HospitalOkinawaJapan
  4. 4.Weight Management and Bariatric-Metabolic Surgery CenterSt. Luke’s Medical CenterQuezon CityPhilippines

Personalised recommendations